PH12013500233A1 - Pharmaceutical composition and method of inhibiting of production or amplifying elimination of p24 protein - Google Patents

Pharmaceutical composition and method of inhibiting of production or amplifying elimination of p24 protein

Info

Publication number
PH12013500233A1
PH12013500233A1 PH1/2013/500233A PH12013500233A PH12013500233A1 PH 12013500233 A1 PH12013500233 A1 PH 12013500233A1 PH 12013500233 A PH12013500233 A PH 12013500233A PH 12013500233 A1 PH12013500233 A1 PH 12013500233A1
Authority
PH
Philippines
Prior art keywords
amplifying
elimination
inhibiting
protein
production
Prior art date
Application number
PH1/2013/500233A
Other languages
English (en)
Inventor
Oleg Iliich Epshtein
Sergey Alexandrovich Tarasov
Original Assignee
Oleg Iliich Epshtein
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oleg Iliich Epshtein filed Critical Oleg Iliich Epshtein
Publication of PH12013500233A1 publication Critical patent/PH12013500233A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PH1/2013/500233A 2010-08-06 2011-07-15 Pharmaceutical composition and method of inhibiting of production or amplifying elimination of p24 protein PH12013500233A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2010133046/15A RU2517084C2 (ru) 2010-08-06 2010-08-06 Способ и средство для ингибирования продукции или усиления элиминации белка р24
PCT/IB2011/002355 WO2012017322A2 (en) 2010-08-06 2011-07-15 Pharmaceutical composition and method of inhibiting of production or amplifying elimination of p24 protein

Publications (1)

Publication Number Publication Date
PH12013500233A1 true PH12013500233A1 (en) 2017-08-23

Family

ID=44899160

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2013/500233A PH12013500233A1 (en) 2010-08-06 2011-07-15 Pharmaceutical composition and method of inhibiting of production or amplifying elimination of p24 protein

Country Status (16)

Country Link
US (2) US20120263726A1 (enExample)
JP (1) JP2013535483A (enExample)
CN (1) CN103179987A (enExample)
AU (1) AU2011287286A1 (enExample)
CA (1) CA2807523A1 (enExample)
DE (1) DE112011102639T5 (enExample)
EA (1) EA029791B1 (enExample)
ES (1) ES2415029R1 (enExample)
GB (1) GB2496356A (enExample)
IT (1) ITTO20110636A1 (enExample)
MX (1) MX2013001450A (enExample)
PH (1) PH12013500233A1 (enExample)
RU (1) RU2517084C2 (enExample)
SG (1) SG187735A1 (enExample)
UA (1) UA112752C2 (enExample)
WO (1) WO2012017322A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2181297C2 (ru) 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
RU2309732C1 (ru) * 2006-03-13 2007-11-10 Олег Ильич Эпштейн Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата
MX2013000543A (es) 2010-07-15 2013-10-28 Oleg Iliich Epshtein Un metodo para aumentar el efecto de una forma activa potenciada de un anticuerpo.
FR2962652A1 (fr) 2010-07-15 2012-01-20 Oleg Iliich Epshtein Composition pharmaceutique d'association et son utilisation dans des procedes pour traiter les maladies ou affections associees a des maladies neurodegeneratives
PH12013500144A1 (en) 2010-07-21 2018-03-21 Oleg Iliich Epshtein A method of treating attention deficit hyperactivity disorder
RU2013111961A (ru) 2013-03-18 2014-09-27 Олег Ильич Эпштейн Способ определения выраженности модифицирующей активности, ассоциированной с носителем
RU2013111962A (ru) 2013-03-18 2014-09-27 Олег Ильич Эпштейн Способ определения выраженности модифицирующей активности, ассоциированной с носителем
RU2603623C2 (ru) * 2014-06-06 2016-11-27 Олег Ильич Эпштейн Ветеринарная композиция и способ улучшения жизнеспособности животных, стимуляции прироста живой массы млекопитающих и птиц, повышения эффективности иммунизации, профилактики и/или лечения инфекционных заболеваний (варианты)

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4311897A (en) 1979-08-28 1982-01-19 Union Carbide Corporation Plasma arc torch and nozzle assembly
DE4236069A1 (de) * 1992-10-26 1994-04-28 Werner Dr Bergmann Arzneimittel, insbesondere für orale Einnahme
US5567604A (en) * 1993-04-23 1996-10-22 Aronex Pharmaceuticals, Inc. Anti-viral guanosine-rich oligonucleotides
CA2268372C (en) * 1996-10-10 2012-11-27 Probe International Compositions and methods for treating viral infections
AU6941000A (en) * 1999-08-27 2001-03-26 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Polypeptides that bind hiv gp120 and related nucleic acids, antibodies, compositions, and methods of use
WO2001043779A2 (en) * 1999-12-16 2001-06-21 Tanox, Inc. Anti-hiv-1 conjugates for treatment of hiv disease
RU2181297C2 (ru) * 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
RU2001134982A (ru) * 2001-12-26 2004-02-20 Олег Ильич Эпштейн Способ коррекции иммунного ответа и лекарственное средство
AU2003246119B2 (en) * 2002-06-28 2008-02-21 Fuso Pharmaceutical Industries, Ltd. Anti-HIV agent
UA76641C2 (uk) 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Гомеопатичний лікарський засіб та спосіб лікування захворювань передміхурової залози
UA76638C2 (en) 2002-08-02 2006-08-15 Oleh Illich Epshtein Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon
AP2005003294A0 (en) * 2002-09-27 2005-06-30 Tanox Inc Synergistic compositions for the prevention and treatment of acquired immunodeficiency syndrome
GB2414670B (en) 2003-03-14 2008-03-19 Nutrition Res Inc Homeopathic formulations useful for treating pain and/or inflammation
RU2393873C2 (ru) * 2005-05-02 2010-07-10 Майметикс Корпорейшн Антитело или его фрагмент, имеющие нейтрализующую активность в отношении вич, но не в отношении il2
RU2315058C1 (ru) * 2006-09-27 2008-01-20 Институт органической химии Уфимского научного центра РАН Гликопептид глицирризиновой кислоты с глицил-l-фенилаланином, проявляющий анти-вич-1 активность
US20120263725A1 (en) * 2010-08-06 2012-10-18 Epshtein Oleg Iiiich Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV

Also Published As

Publication number Publication date
ES2415029R1 (es) 2013-09-17
US20130315964A1 (en) 2013-11-28
MX2013001450A (es) 2013-10-25
US20120263726A1 (en) 2012-10-18
WO2012017322A3 (en) 2012-04-19
WO2012017322A2 (en) 2012-02-09
EA201300138A1 (ru) 2014-03-31
UA112752C2 (uk) 2016-10-25
RU2010133046A (ru) 2012-02-20
SG187735A1 (en) 2013-03-28
GB2496356A (en) 2013-05-08
AU2011287286A1 (en) 2013-03-14
ES2415029A2 (es) 2013-07-23
CN103179987A (zh) 2013-06-26
RU2517084C2 (ru) 2014-05-27
CA2807523A1 (en) 2012-02-09
GB201303865D0 (en) 2013-04-17
EA029791B1 (ru) 2018-05-31
JP2013535483A (ja) 2013-09-12
ES2415029A8 (es) 2013-09-16
DE112011102639T5 (de) 2013-10-02
ITTO20110636A1 (it) 2012-02-07

Similar Documents

Publication Publication Date Title
MX336682B (es) Anticuerpos contra csf-1r humanos y usos de los mismos.
MX356337B (es) Anticuerpos contra csf-1r humano y sus usos.
TW201129381A (en) Antibodies against human CSF-1R and uses thereof
PH12013500233A1 (en) Pharmaceutical composition and method of inhibiting of production or amplifying elimination of p24 protein
PH12012501157A1 (en) Anti-her3 antibodies and uses thereof
BR112012024312A2 (pt) anticorpos biespecíficos
CY1119143T1 (el) Διεργασια για την παρασκευη παραγωγων και ενδιαμεσων καρβαμουλοπυριδονης
MX2013001045A (es) Organoide hepatico, sus usos y metodo de cultivo para obtenerlos.
MX2019006362A (es) Una combinacion de inmunoconjugado y anticuerpo para usarse en el tratamiento de cancer.
PH12014502010A1 (en) Bispecific antibodies against human tweak and human il17 and uses thereof
PH12014501427A1 (en) Anti-php-tau antibodies and their uses
MX2012007676A (es) Nueva formulacion de anticuerpo.
MY187874A (en) Antibody formulations
MX340558B (es) Anticuerpos biespecificos que comprenden fragmento fv estabilizado con disulfuro.
MX2013009151A (es) Inmunoterapia mejorada.
PH12013501821A1 (en) Solid forms of 3-(5-amino-2methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses
AU2011217848A8 (en) Integrin aVB8 neutralizing antibody
MX359288B (es) Forma iv del clorhidrato de ivabradina.
GB2497453A (en) Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV
UA116889C2 (uk) Фармацевтична композиція, що містить суміш ізоформ apg101 (cd95-fc)
PH12013500554A1 (en) Process for preparing pan-cdk inhibitors of the formula (i) and intermediates in the preparation
MX2015003034A (es) Jeringa que contiene una composicion, en particular farmaceutica, que comprende inmunoglobulinas, su metodo de fabricacion y uso.
MX2014004210A (es) Derivados de 2-oxo-piperidinilo.
MX2012010317A (es) ß-HIDROXIALQUILAMIDAS, METODO PARA SU PRODUCCION Y SU USO.
MX349563B (es) Formulacion farmaceutica de fenofibrato nanonizado.